Erdheim-Chester disease
Information
- Disease name
- Erdheim-Chester disease
- Disease ID
- DOID:4329
- Description
- "A non-Langerhans-cell histiocytosis that is characterized by the proliferation in the tissues of lipid-laden macrophages and the presence of multinucleated giant cells. It results in sclerosis of the long bones and failure of the affected organs." [url:https\://medlineplus.gov/genetics/condition/erdheim-chester-disease/, url:https\://rarediseases.org/rare-diseases/erdheim-chester-disease/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01552434 | Active, not recruiting | Phase 1 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | March 16, 2012 | March 31, 2026 |
| NCT05092815 | Active, not recruiting | Phase 2 | The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation | December 6, 2021 | October 30, 2024 |
| NCT02608619 | Completed | Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement | November 2015 | August 2018 | |
| NCT06332183 | Recruiting | GWAS and EWAS in Patients With Erdheim-Chester Disease | July 17, 2019 | October 1, 2024 | |
| NCT03329274 | Recruiting | Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses | October 26, 2017 | October 2024 | |
| NCT05093335 | Recruiting | Early Phase 1 | In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET | October 1, 2021 | October 2025 |
| NCT05768178 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | March 1, 2023 | October 2029 |
| NCT05915208 | Recruiting | Histiocytic Disorder Follow-up Study | September 1, 2022 | December 2028 | |
| NCT06317246 | Recruiting | N/A | Subtypes and Prognostic Factors in Erdheim-Chester Disease | September 15, 2020 | December 15, 2024 |
| NCT04079179 | Recruiting | Phase 2 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | April 19, 2021 | December 2029 |
| NCT01727206 | Terminated | Phase 2 | Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease | November 2012 | December 2015 |
| NCT04198818 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | January 7, 2020 | March 31, 2023 |
| NCT02089724 | Unknown status | Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease | March 2014 | April 2019 | |
| NCT03794297 | Withdrawn | Phase 2 | Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations | January 4, 2019 | February 18, 2021 |
- Disase is a (Disease Ontology)
- DOID:4330
- Cross Reference ID (Disease Ontology)
- GARD:6369
- Cross Reference ID (Disease Ontology)
- ICDO:9749/3
- Cross Reference ID (Disease Ontology)
- MESH:D031249
- Cross Reference ID (Disease Ontology)
- NCI:C53972
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:703711007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0878675
- OrphaNumber from OrphaNet (Orphanet)
- 35687
- MeSH unique ID (MeSH (Medical Subject Headings))
- D031249